- Home
- OKYO vs GRCE Comparison
OKYO vs GRCE Comparison
Compare OKYO & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- GRCE
- Stock Information
- Founded
- OKYO 2007
- GRCE 2002
- Country
- OKYO United Kingdom
- GRCE United States
- Employees
- OKYO N/A
- GRCE N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- GRCE
- Sector
- OKYO Health Care
- GRCE
- Exchange
- OKYO Nasdaq
- GRCE NYSE
- Market Cap
- OKYO 37.0M
- GRCE 42.1M
- IPO Year
- OKYO 2022
- GRCE N/A
- Fundamental
- Price
- OKYO $2.41
- GRCE $2.94
- Analyst Decision
- OKYO Strong Buy
- GRCE Strong Buy
- Analyst Count
- OKYO 1
- GRCE 1
- Target Price
- OKYO $7.00
- GRCE $12.00
- AVG Volume (30 Days)
- OKYO 213.3K
- GRCE 53.0K
- Earning Date
- OKYO 08-12-2025
- GRCE 06-23-2025
- Dividend Yield
- OKYO N/A
- GRCE N/A
- EPS Growth
- OKYO N/A
- GRCE N/A
- EPS
- OKYO N/A
- GRCE N/A
- Revenue
- OKYO N/A
- GRCE N/A
- Revenue This Year
- OKYO N/A
- GRCE N/A
- Revenue Next Year
- OKYO N/A
- GRCE N/A
- P/E Ratio
- OKYO N/A
- GRCE N/A
- Revenue Growth
- OKYO N/A
- GRCE N/A
- 52 Week Low
- OKYO $0.81
- GRCE $1.75
- 52 Week High
- OKYO $3.11
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- OKYO 58.01
- GRCE N/A
- Support Level
- OKYO $2.05
- GRCE N/A
- Resistance Level
- OKYO $2.49
- GRCE N/A
- Average True Range (ATR)
- OKYO 0.31
- GRCE 0.00
- MACD
- OKYO -0.01
- GRCE 0.00
- Stochastic Oscillator
- OKYO 44.44
- GRCE 0.00
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.